PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma
about
The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in VivoRad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
P2860
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PARP inhibitor olaparib increa ...... f anaplastic thyroid carcinoma
@en
type
label
PARP inhibitor olaparib increa ...... f anaplastic thyroid carcinoma
@en
prefLabel
PARP inhibitor olaparib increa ...... f anaplastic thyroid carcinoma
@en
P2093
P2860
P50
P1433
P1476
PARP inhibitor olaparib increa ...... f anaplastic thyroid carcinoma
@en
P2093
Eloise Scamardella
Ginevra Botta
Giuseppe Perruolo
Giuseppe Portella
Silvana Libertini
P2860
P356
10.1016/J.MOLONC.2014.07.022
P577
2014-08-02T00:00:00Z